FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

Check this box if no longer subject to	0
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GAROFALO ELIZABETH A. (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD									heck all appli X Director Office	ationship of Reporting k all applicable) Director Officer (give title below)		10% Ov Other (s below)	wner
C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 09/29/2020													
(Street) SAN DII		ate) (92130 (Zip)	Deriva	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Application) X Form filed by One Reporting Person Form filed by More than One Reporting Person Person ative Securities Acquired, Disposed of, or Beneficially Owned								n					
1. Title of Security (Instr. 3) 2. Transa Date (Month/E				2. Transa Date	ction 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8) 4. Securi Disposed 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following Reported				7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	ransaction of Exp Code (Instr. Derivative (Mo		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$40.41	09/29/2020			A		6,865		(1)	09	9/28/2030	Common Stock	6,865	\$0.00	6,865		D	
Restricted Stock Units	(2)	09/29/2020			A		3,837		(3)		(3)	Common Stock	3,837	\$0.00	3,837		D	

Explanation of Responses:

- 1. The shares subject to the stock option shall vest in two equal annual installments commencing on the first anniversary of the grant date.
- 2. Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
- 3. The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date.

Remarks:

/s/ Austin D. Kim, Attorney-in-10/01/2020 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.